JP2017519784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519784A5 JP2017519784A5 JP2016575488A JP2016575488A JP2017519784A5 JP 2017519784 A5 JP2017519784 A5 JP 2017519784A5 JP 2016575488 A JP2016575488 A JP 2016575488A JP 2016575488 A JP2016575488 A JP 2016575488A JP 2017519784 A5 JP2017519784 A5 JP 2017519784A5
- Authority
- JP
- Japan
- Prior art keywords
- linked
- pharmaceutical composition
- composition according
- optionally substituted
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 86
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 25
- -1 α-amino acid ester Chemical class 0.000 claims 24
- 235000008206 alpha-amino acids Nutrition 0.000 claims 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 16
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 10
- 235000004279 alanine Nutrition 0.000 claims 10
- 229960000310 isoleucine Drugs 0.000 claims 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 239000004474 valine Substances 0.000 claims 10
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 9
- 239000004475 Arginine Substances 0.000 claims 8
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 8
- 239000004471 Glycine Substances 0.000 claims 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- 239000004472 Lysine Substances 0.000 claims 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 8
- 239000004473 Threonine Substances 0.000 claims 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 8
- 235000009582 asparagine Nutrition 0.000 claims 8
- 229960001230 asparagine Drugs 0.000 claims 8
- 235000018417 cysteine Nutrition 0.000 claims 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 8
- 229930195712 glutamate Natural products 0.000 claims 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 8
- 229930182817 methionine Natural products 0.000 claims 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 6
- 125000005907 alkyl ester group Chemical group 0.000 claims 6
- 229940009098 aspartate Drugs 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 150000007860 aryl ester derivatives Chemical class 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 241000711573 Coronaviridae Species 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 241001502567 Chikungunya virus Species 0.000 claims 1
- 241001122120 Hepeviridae Species 0.000 claims 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 1
- 102220587413 N-acetylserotonin O-methyltransferase-like protein_R23A_mutation Human genes 0.000 claims 1
- 102220587418 N-acetylserotonin O-methyltransferase-like protein_R24A_mutation Human genes 0.000 claims 1
- 102220479492 NAD(+) hydrolase SARM1_R22A_mutation Human genes 0.000 claims 1
- 241000150350 Peribunyaviridae Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000710924 Togaviridae Species 0.000 claims 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- FYGSULGPSNHJFD-LUTQBAROSA-N C#C[C@@]([C@@H]1O)([C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@@]1(COP(O)(OP(O)(OP(O)(O)=O)=O)=O)F)F Chemical compound C#C[C@@]([C@@H]1O)([C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@@]1(COP(O)(OP(O)(OP(O)(O)=O)=O)=O)F)F FYGSULGPSNHJFD-LUTQBAROSA-N 0.000 description 1
- MAYPBRYPGCIUGY-FPQZTECRSA-N CC([C@@]([C@@H]1F)([C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@@]1(COP(O)(OP(O)(OP(O)(O)=O)=O)=O)F)O)=C Chemical compound CC([C@@]([C@@H]1F)([C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@@]1(COP(O)(OP(O)(OP(O)(O)=O)=O)=O)F)O)=C MAYPBRYPGCIUGY-FPQZTECRSA-N 0.000 description 1
- GRVAKIGJYFCAOR-LGVRLFTQSA-N CCOc1c2nc[n]([C@@H]([C@]3(C)F)OCC3(COP(NC(C)C(OC(C)C)=O)(Oc3ccccc3)=O)O)c2nc(N)n1 Chemical compound CCOc1c2nc[n]([C@@H]([C@]3(C)F)OCC3(COP(NC(C)C(OC(C)C)=O)(Oc3ccccc3)=O)O)c2nc(N)n1 GRVAKIGJYFCAOR-LGVRLFTQSA-N 0.000 description 1
- POYJEGXPYNEDOC-OUVAMTEUSA-N CCOc1nc(N)nc2c1nc[n]2[C@@H]([C@@](C)([C@@H]1F)O)O[C@@]1(COP(OCOC(OC(C)C)=O)(OCOC(OC(C)C)=O)=O)F Chemical compound CCOc1nc(N)nc2c1nc[n]2[C@@H]([C@@](C)([C@@H]1F)O)O[C@@]1(COP(OCOC(OC(C)C)=O)(OCOC(OC(C)C)=O)=O)F POYJEGXPYNEDOC-OUVAMTEUSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016232P | 2014-06-24 | 2014-06-24 | |
| US62/016,232 | 2014-06-24 | ||
| US201462061770P | 2014-10-09 | 2014-10-09 | |
| US62/061,770 | 2014-10-09 | ||
| PCT/US2015/037001 WO2015200219A1 (en) | 2014-06-24 | 2015-06-22 | Substituted nucleosides, nucleotides and analogs thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114136A Division JP7080928B2 (ja) | 2014-06-24 | 2020-07-01 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519784A JP2017519784A (ja) | 2017-07-20 |
| JP2017519784A5 true JP2017519784A5 (cg-RX-API-DMAC7.html) | 2018-09-13 |
| JP6728075B2 JP6728075B2 (ja) | 2020-07-22 |
Family
ID=54868668
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575488A Active JP6728075B2 (ja) | 2014-06-24 | 2015-06-22 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
| JP2020114136A Active JP7080928B2 (ja) | 2014-06-24 | 2020-07-01 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
| JP2022085181A Active JP7449978B2 (ja) | 2014-06-24 | 2022-05-25 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114136A Active JP7080928B2 (ja) | 2014-06-24 | 2020-07-01 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
| JP2022085181A Active JP7449978B2 (ja) | 2014-06-24 | 2022-05-25 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
Country Status (20)
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2794627T3 (pl) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EA201590943A1 (ru) | 2012-12-21 | 2016-01-29 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| HK1216535A1 (zh) | 2012-12-21 | 2016-11-18 | Alios Biopharma, Inc. | 取代的核苷、核苷酸及其類似物 |
| US9504705B2 (en) | 2013-04-05 | 2016-11-29 | Alios Biopharma, Inc. | Hepatitis C viral infection treatment using a combination of compounds |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| ES2952714T3 (es) | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
| SG10201804835VA (en) * | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| SG11201610599TA (en) | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015200205A1 (en) | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EA031726B1 (ru) | 2014-09-26 | 2019-02-28 | Рибосайенс Ллк | 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса |
| CN107108681B (zh) | 2014-10-28 | 2021-04-06 | 詹森生物制药有限公司 | 制备取代的核苷类似物的方法 |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| CN107427529A (zh) | 2014-12-26 | 2017-12-01 | 埃莫里大学 | N4‑羟基胞苷和衍生物及与其相关的抗病毒用途 |
| KR102363946B1 (ko) | 2015-03-06 | 2022-02-17 | 아테아 파마슈티컬즈, 인크. | HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드 |
| CA2979216A1 (en) | 2015-03-11 | 2016-09-15 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| CN105503787A (zh) * | 2015-12-31 | 2016-04-20 | 阜阳欣奕华材料科技有限公司 | 一种索非布韦中间体的纯化方法 |
| PT3433257T (pt) | 2016-03-24 | 2023-11-29 | Novartis Ag | Análogos nucleosídeos de alquinil como inibidores do rinovírus humano |
| EA201892448A1 (ru) * | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| HRP20220278T1 (hr) | 2016-09-07 | 2022-05-13 | Atea Pharmaceuticals, Inc. | 2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima |
| JP7125144B2 (ja) | 2016-09-09 | 2022-08-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| US11643432B2 (en) | 2016-12-16 | 2023-05-09 | National University Corporation Tokai National Higher Education And Research System | Nucleoside derivative and use thereof |
| IL295609B2 (en) | 2017-02-01 | 2023-11-01 | Atea Pharmaceuticals Inc | Nucleotide hemisulfate salt for the treatment of hepatitis C virus |
| JP2020518578A (ja) | 2017-05-01 | 2020-06-25 | ギリアード サイエンシーズ， インコーポレイテッド | （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態 |
| CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CA3071612A1 (en) | 2017-07-31 | 2019-02-07 | January Therapeutics, Inc. | Organophosphate derivatives |
| CR20200126A (es) | 2017-09-18 | 2020-07-11 | Janssen Biopharma Inc | Nucleósidos sustituidos, nucleótidos y análogos de estos |
| WO2019088179A1 (ja) | 2017-10-31 | 2019-05-09 | ヤマサ醤油株式会社 | ヌクレオシド誘導体及びその利用 |
| ES2995458T3 (en) | 2017-12-07 | 2025-02-10 | Univ Emory | N4-hydroxycytidine derivative and anti-viral uses related thereto |
| AU2019227986A1 (en) * | 2018-03-02 | 2020-10-08 | January Therapeutics, Inc. | Nanoparticle compositions |
| CN119633010A (zh) * | 2018-03-07 | 2025-03-18 | 埃默里大学 | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 |
| WO2019200005A1 (en) | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| MA55200A (fr) | 2019-03-06 | 2022-01-12 | Glaxosmithkline Ip No 2 Ltd | Composés utiles dans la thérapie du vih |
| KR20240113860A (ko) * | 2019-04-05 | 2024-07-23 | 가부시기가이샤 닛뽕쇼꾸바이 | 가교형 인공 뉴클레오시드의 제조 |
| WO2021137913A2 (en) * | 2019-10-08 | 2021-07-08 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN118766947A (zh) | 2020-01-27 | 2024-10-15 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| EP4644394A2 (en) | 2020-02-18 | 2025-11-05 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN113387954B (zh) * | 2020-03-11 | 2024-03-19 | 上海特化医药科技有限公司 | 一种瑞德西韦中间体的制备方法 |
| TWI890963B (zh) | 2020-03-12 | 2025-07-21 | 美商基利科學股份有限公司 | 1'-氰基核苷之製備方法 |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CN115335387A (zh) * | 2020-03-27 | 2022-11-11 | 住友化学株式会社 | 核酸寡聚物的制造方法 |
| EP4125912B1 (en) * | 2020-03-27 | 2025-07-30 | R.G.C.C. Holdings AG | Compounds for the in vitro inhibition of the rna-dependent rna polymerase of coronaviruses |
| CN115362004A (zh) | 2020-04-06 | 2022-11-18 | 吉利德科学公司 | 1’-氰基取代的碳核苷类似物的吸入制剂 |
| UY39172A (es) * | 2020-04-14 | 2021-10-29 | Janssen Sciences Ireland Unlimited Co | Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| JP2023531524A (ja) | 2020-06-24 | 2023-07-24 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシド類似体及びその使用 |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| IL300453A (en) | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| CN112279877B (zh) * | 2020-12-15 | 2021-08-06 | 南京颐媛生物医学研究院有限公司 | 一种核苷磷酸酯及其合成方法 |
| CN113214320A (zh) * | 2021-01-23 | 2021-08-06 | 河南泰丰生物科技有限公司 | 一种瑞德西韦化合物的制备方法 |
| WO2022174194A1 (en) * | 2021-02-15 | 2022-08-18 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| BR112023020600A2 (pt) * | 2021-04-09 | 2023-12-12 | Univ Emory | Método para tratar ou prevenir uma infecção, e, uso de um composto |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| MX2023014898A (es) | 2021-06-17 | 2024-04-29 | Atea Pharmaceuticals Inc | Terapia combinada anti-vhc ventajosa. |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| CN113735929A (zh) * | 2021-07-21 | 2021-12-03 | 海化生命(厦门)科技有限公司 | 一种抗冠状病毒的化合物及其制备方法与应用 |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| CN115721661A (zh) * | 2021-09-01 | 2023-03-03 | 常晓宇 | 嘌呤核苷类药物预防或治疗冠状病毒感染性疾病的用途 |
| CN113461760B (zh) * | 2021-09-06 | 2021-12-10 | 南京颐媛生物医学研究院有限公司 | 4-硫代脱氧胸苷衍生物及其抗乙肝病毒制药应用 |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| WO2023069495A1 (en) * | 2021-10-19 | 2023-04-27 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides |
| US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| CN116554249B (zh) * | 2022-01-28 | 2025-03-18 | 北京恩泰伟医药科技有限公司 | 抗病毒化合物及其用途 |
| TW202525810A (zh) | 2022-03-02 | 2025-07-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| JP2025509635A (ja) | 2022-03-15 | 2025-04-11 | ローム・セラピューティクス・インコーポレイテッド | 疾患を治療するための化合物及び方法 |
| US20250282812A1 (en) * | 2022-04-20 | 2025-09-11 | Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences | Antiviral nucleoside analogue, and pharmaceutical composition and use thereof |
| JPWO2024034644A1 (cg-RX-API-DMAC7.html) * | 2022-08-10 | 2024-02-15 | ||
| WO2024086592A2 (en) * | 2022-10-17 | 2024-04-25 | Emory Unversity | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN116589510B (zh) * | 2023-04-20 | 2025-08-26 | 安徽大学 | 一种氟代苄基核糖中间体的制备方法与应用 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| PT2251015E (pt) | 2000-10-18 | 2013-04-15 | Gilead Pharmasset Llc | Nucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal |
| BR0206614A (pt) | 2001-01-22 | 2004-02-17 | Merck & Co Inc | Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto |
| JP2005533817A (ja) * | 2002-06-28 | 2005-11-10 | イデニクス（ケイマン）リミテツド | フラビウィルス科ウィルス感染治療用の修飾２′および３′−ヌクレオシドプロドラッグ |
| US20040259934A1 (en) * | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| WO2005020884A2 (en) * | 2003-05-14 | 2005-03-10 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| JP2008508319A (ja) * | 2004-07-29 | 2008-03-21 | メタバシス・セラピューティクス・インコーポレイテッド | 新規ヌクレオシド誘導体 |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8633308B2 (en) * | 2007-02-28 | 2014-01-21 | The Governors Of The University Of Alberta | Compounds for preventing or treating viral infections and methods of use thereof |
| WO2010015643A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| EP2408306A4 (en) | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES |
| US20100240604A1 (en) * | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
| EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| CA2810928A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2012040126A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| CN102558261A (zh) * | 2010-12-17 | 2012-07-11 | 中国科学院大连化学物理研究所 | 一种核苷酸类似物及其合成和应用 |
| WO2012088155A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| CN103687866A (zh) * | 2011-05-19 | 2014-03-26 | Rfs制药公司 | 用于治疗病毒性感染的嘌呤单磷酸酯前药 |
| SG11201403364PA (en) | 2011-12-20 | 2014-07-30 | Hoffmann La Roche | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
| US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| PL2794627T3 (pl) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| WO2013142159A1 (en) | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| UA113980C2 (uk) | 2012-03-21 | 2017-04-10 | Аліос Біофарма, Інк. | Заміщені нуклеозиди, нуклеотиди і їх аналоги |
| NZ630800A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Methods of preparing substituted nucleotide analogs |
| NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
| US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| FR3000193B1 (fr) | 2012-12-20 | 2015-01-16 | Msc & Sgcc | Procede et dispositif de mesure de la verticalite sur un recipient |
| EA201590943A1 (ru) | 2012-12-21 | 2016-01-29 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| HK1216535A1 (zh) | 2012-12-21 | 2016-11-18 | Alios Biopharma, Inc. | 取代的核苷、核苷酸及其類似物 |
| TW201526899A (zh) | 2013-02-28 | 2015-07-16 | Alios Biopharma Inc | 醫藥組成物 |
| US20140309413A1 (en) | 2013-03-11 | 2014-10-16 | Vertex Pharmaceuticals Incorporated | Methods of stereoselective synthesis of substituted nucleoside analogs |
| US9504705B2 (en) | 2013-04-05 | 2016-11-29 | Alios Biopharma, Inc. | Hepatitis C viral infection treatment using a combination of compounds |
| AU2014250764A1 (en) | 2013-04-12 | 2015-10-29 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating HCV |
| ES2952714T3 (es) | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| SG10201804835VA (en) | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015200205A1 (en) | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| SG11201610599TA (en) | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| AU2015280245A1 (en) | 2014-06-24 | 2017-01-05 | Alios Biopharma, Inc. | Methods of preparing substituted nucleotide analogs |
| WO2016014398A1 (en) | 2014-07-22 | 2016-01-28 | Alios Biopharma, Inc. | Methods for treating paramyxoviruses |
| CA2957017A1 (en) | 2014-08-05 | 2016-02-11 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
| CN107108681B (zh) | 2014-10-28 | 2021-04-06 | 詹森生物制药有限公司 | 制备取代的核苷类似物的方法 |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| TW201811339A (zh) | 2016-08-12 | 2018-04-01 | 美商艾洛斯生物製藥公司 | 經取代之核苷、核苷酸及其類似物 |
| WO2018081449A1 (en) | 2016-10-27 | 2018-05-03 | Alios Biopharma, Inc. | Methods for treating respiratory syncytial virus infection |
-
2015
- 2015-06-22 SG SG11201610599TA patent/SG11201610599TA/en unknown
- 2015-06-22 EA EA201692535A patent/EA201692535A1/ru unknown
- 2015-06-22 SI SI201531469T patent/SI3160476T1/sl unknown
- 2015-06-22 HR HRP20202014TT patent/HRP20202014T1/hr unknown
- 2015-06-22 LT LTEP15812231.7T patent/LT3160476T/lt unknown
- 2015-06-22 ES ES15812231T patent/ES2841310T3/es active Active
- 2015-06-22 DK DK15812231.7T patent/DK3160476T3/da active
- 2015-06-22 CN CN201580045439.9A patent/CN106573011A/zh active Pending
- 2015-06-22 HU HUE15812231A patent/HUE051986T2/hu unknown
- 2015-06-22 SM SM20200716T patent/SMT202000716T1/it unknown
- 2015-06-22 EP EP15812231.7A patent/EP3160476B1/en active Active
- 2015-06-22 JP JP2016575488A patent/JP6728075B2/ja active Active
- 2015-06-22 EP EP20192890.0A patent/EP3797782A1/en not_active Ceased
- 2015-06-22 CA CA3207106A patent/CA3207106A1/en active Pending
- 2015-06-22 US US14/746,500 patent/US9603864B2/en active Active
- 2015-06-22 AU AU2015280248A patent/AU2015280248B2/en active Active
- 2015-06-22 MX MX2016017383A patent/MX2016017383A/es unknown
- 2015-06-22 WO PCT/US2015/037001 patent/WO2015200219A1/en not_active Ceased
- 2015-06-22 CA CA2952966A patent/CA2952966C/en active Active
- 2015-06-22 CN CN202310927143.6A patent/CN117379452A/zh active Pending
- 2015-06-24 TW TW104120371A patent/TW201613612A/zh unknown
-
2016
- 2016-12-18 IL IL249628A patent/IL249628A0/en unknown
- 2016-12-21 PH PH12016502564A patent/PH12016502564A1/en unknown
-
2017
- 2017-02-02 US US15/423,270 patent/US10307439B2/en active Active
-
2020
- 2020-07-01 JP JP2020114136A patent/JP7080928B2/ja active Active
-
2021
- 2021-07-08 AU AU2021204791A patent/AU2021204791B2/en active Active
-
2022
- 2022-05-25 JP JP2022085181A patent/JP7449978B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519784A5 (cg-RX-API-DMAC7.html) | ||
| JP2020172511A5 (cg-RX-API-DMAC7.html) | ||
| JP2012521359A5 (cg-RX-API-DMAC7.html) | ||
| MX384836B (es) | Agentes antivirales contra la hepatitis b | |
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| BR112018075465A2 (pt) | agentes antivirais de hepatite b | |
| CY1120778T1 (el) | Αναστολεις αντιγραφης ιων γριπης | |
| HRP20202014T1 (hr) | Supstituirani nukleozidi, nukleotidi i njihovi analozi za uporabu u liječenju virusne infekcije | |
| CY1114892T1 (el) | Φαρμακευτικη συνθεση ενος ισχυρου αναστολεα του hcv για απο του στοματος χορηγηση | |
| BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| JP2015510946A5 (cg-RX-API-DMAC7.html) | ||
| MX2014001497A (es) | Profarmacos de trepostinil enlazados a un portador. | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| RU2014133818A (ru) | Стабилизированный состав pth | |
| JP2017515901A5 (cg-RX-API-DMAC7.html) | ||
| JP2017518334A5 (cg-RX-API-DMAC7.html) | ||
| CA2753382C (en) | Hepatitis c virus inhibitors | |
| JP2013537907A5 (cg-RX-API-DMAC7.html) | ||
| JP2016006096A5 (cg-RX-API-DMAC7.html) | ||
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| EP2555622A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| CY1117177T1 (el) | Διεργασια για την παρασκευη [(3-υδροξυπυριδινο-2-καρβονυλ)αμινο]αλκανοϊκων οξεων, εστερων και αμιδιων | |
| MA32633B1 (fr) | Formes cristallines d'un derive 2-thiazolyl-4-quinolinyl-oxy, un inhibiteur puissant du vhc | |
| WO2013059278A3 (en) | Hepatitis c virus inhibitors |